A clinical trial is any research study that evaluates interventions to prevent, detect, diagnose, or treat a disease or disorder. In a clinical trial, human participants (or groups of participants) are assigned to one or more interventions to assess the results on health outcomes.
Clinical Trials are important in discovering new treatments to prevent, detect, diagnose or treat Narcolepsy. It is the only process to bring new pharmacological drugs and treatments forward for approval to use within the Narcolepsy community. Without the clinical trials, there is a risk that individuals could be given treatments which have no advantage, waste time and could even be harmful to one’s health. If a treatment has no benefit, or has serious side effects, the treatment may not be further developed.
The Vibrance-2 Study is researching an investigational oral study drug for the potential treatment of excessive daytime sleepiness symptoms. Adults 18-70 years of age with narcolepsy type 2 are invited to learn more about this important sleep disorder research.
Stanford University and Mayo Clinic have partnered to evaluate the efficacy of low sodium oxybate on total sleep time in patients with idiopathic hypersomnia. The comprehensive assessments will yield detailed information about how low sodium oxybate affects sleep, breathing, and other physiological metrics, ultimately enhancing understanding of idiopathic hypersomnia.
The Vibrance-1 Study is researching an investigational oral study drug for the potential treatment of excessive daytime sleepiness symptoms. Adults 18-70 years of age with narcolepsy type 1 are invited to learn more about this important sleep disorder research.
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1).
The DUET Study will evaluate daytime and nighttime effects of XYWAV® (low-sodium oxybate oral solution), also known as JZP258, in people with idiopathic hypersomnia (IH) or narcolepsy (Type 1 or Type 2).
This is a study looking at blood pressure in people with narcolepsy. We want to understand more about blood pressure when people with narcolepsy change from a high-sodium oxybate medication, like XYREM, to the study medication, XYWAV. XYWAV has the same active ingredients as XYREM, but with a much lower sodium content.
Superior Clinical Research in North Carolina is recruiting participants for a groundbreaking narcolepsy study. If you or someone you know is living with narcolepsy, this is an opportunity to contribute to important research that could lead to better treatments and improved quality of life. Learn more and see if you qualify today!
Because partial or complete Orexin receptor deficiency plays an important role in the development of EDS, orexin replacement therapy may improve EDS through a pathophysiology-directed mechanism of action. We are currently investigating a new novel drug that acts to help address the deficiency of orexin-2 receptor agonists that may address the spectrum of narcolepsy symptoms and have greater efficacy than currently approved drugs for EDS and cataplexy.
Mayo Clinic Jacksonville is conducting a survey to study the effect of lifestyle factors in narcolepsy and idiopathic hypersomnia patients due to a lack of knowledge in this area.
Narcolepsy researchers are conducting a survey study of adults with type 1 narcolepsy and recent pregnancies in order to assess the impact of narcolepsy on pregnancy, and vice versa.
Boston Children’s Hospital developed a website to help 10 to 17 year olds with narcolepsy or idiopathic hypersomnia and their families better understand how their sleep disorder could affect their social health (e.g., with friends, at school with teachers), and strategies to improve these relationships. Study participants will receive a $50 debit card after completing brief surveys.
In efforts to modernize clinical measurements of sleepiness, Stanford physicians partnered with the UK biobank to develop the Situational Sleepiness Scale.
Global Perspectives, an organization specialized in healthcare studies, is conducting a study to understand the relationship between narcolepsy symptoms and their effect on well-being.
IQVIA is currently looking for adults (≥18 years of age) who have been diagnosed with narcolepsy or IH currently taking Xywav® to take part in a paid research study.
Validation of Pediatric Narcolepsy Patient Reported Outcomes (PN-PROS)
Looking for participants with narcolepsy to complete a survey for a Grand State Valley University graduate study.
Please help us improve the clinical trial for patients.